Biotech | January 07, 2022
Lilly and Entos collaborate for therapies in multiple neurologic indications
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
It plans to deliver over 300 million doses to the Indian government
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Subscribe To Our Newsletter & Stay Updated
